Abstract
Opioid dependence is a national crisis, with 30 million patients annually at risk of becoming persistent opioid users after receiving opioids for post-surgical pain management. Translational Pain Services (TPS) demonstrate effectiveness for behavioral health improvements but its effectiveness in preventing persistent opioid use is less established, especially amongst opioid exposed patients. Prohibitive costs and accessibility challenges have hindered TPS program adoption. To address these limitations, we designed and implemented a remote telehealth TPS protocol focusing on preventing continued opioid use while improving behavioral health. Licensed therapists trained in the opioid-tapering CBT protocol delivered sessions reimbursed through standard payer reimbursement. Our prospective study evaluated the protocol’s effectiveness on preventing persistent opioid use and behavioral health outcomes amongst both opioid naïve and exposed patients. In an opioid-naive patient cohort (n=67), 100% completely tapered off opioids, while in an opioid-exposed cohort (n =19) 52% completely tapered off opioids, demonstrating promising results. In both cohorts, we observed significant improvements in behavioral health scores, including pain. This opioid-tapering digital TPS is effective, adoptable, and incurs no out-of-pocket cost for healthcare systems. We provide the opioid-tapering CBT protocol in the supplement to facilitate adoption. Trial Registration Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines registered at clinicaltrials.gov, NCT04787692. https://clinicaltrials.gov/ct2/show/NCT04787692?term=NCT04787692&draw=2&rank=1
Competing Interest Statement
MH is a salaried employee of Lucid Lane, Inc., has stock options in Lucid Lane, Inc., and has received conference travel support from Lucid Lane, Inc. BN is a salaried employee of Lucid Lane, Inc. and Anthem, Inc., has stock options in Lucid Lane, Inc. and Anthem, Inc., and has patents planned from Lucid Lane, Inc. and Anthem, Inc. AZ is a salaried employee of Lucid Lane, Inc., and Lucid Lane Providers, P.C., has received travel support from Lucid Lane, Inc., is on the leadership board of Lucid Lane and Board of Directors, and is on the Advisory Board of the American Festival for Thy Arts. JS has no competing interests. JC has received teaching payment from Stryker Spine. AF has grant support from NIH NINDS R01 #NS113893, and participates on the Data Safety Monitoring Board/Advisory Board of Medtronic. EP served as President for the Texas Society of Anesthesiologists, and serves as a Medical Consultant with future stock options at Lucid Lane, Inc.
Clinical Trial
NCT04787692
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Committee for the Protection of Human Subjects at the University of Texas Health Science Center Houston (Institutional Review Board NUMBER: HSC-MS-20-0549) approved the study. All participants gave verbal and written consent to participate. The study was registered at clinicaltrials.gov, identifier NCT04787692.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All data will be made available upon publication. It will be available in deidentified format.
